Table 1. Patient characteristics.

case #	age	gender	location	size [cm]	risk	ABL1	KIT
1	43	F	unknown (m)	mult.	high/metastatic	3	3
2	66	M	small bowel	2.0	none	3	3
3	71	M	stomach	14.0	high	3	0.5
4	50	F	small bowel	4.0	low	2	3
5	65	F	small bowel	5.0	low	2	3
6	44	F	rectum	4.0	high	2	2.5
7	27	M	small bowel	4.5	low	2	2
8	76	M	stomach	5.0	very low	2	2
9	79	M	small bowel	1.5	none	2	2
10	61	M	stomach	21.0	high	2	1.5
11	68	M	unknown (m)	> 10.0	high/metastatic	2	1.5
12	81	M	stomach	6.5	low	2	1
13	92	F	stomach	9.0	low	2	0
14	52	M	small bowel	1.8	none	1.5	2
15	66	M	stomach	13.0	high	1.5	1
16	72	F	stomach	4.0	very low	1.5	0.5
17	43	F	stomach	8.0	low	1	2.5
18	66	M	unknown (m)	mult.	high/metastatic	1	2
19	80	M	small bowel	2.5	low	1	2
20	58	F	stomach	13.0	intermediate	1	1.5
21	78	M	stomach	1.5	none	1	1
22	64	M	stomach	2.0	none	1	1
23	75	F	stomach	4.0	very low	1	0.5
24	82	M	colon	6.0	high	1	0
25	69	F	stomach	3.5	very low	0.5	2
26	32	F	stomach	0.7	none	0.5	1
27	57	M	retroperitoneum	20.0	high/metastatic	0.5	0.5
28	69	M	stomach	1.0	n/a	n/a	n/a

Cases are grouped according to their ABL1 expression levels (from high to low). No correlation with age, gender, tumor location, tumor size or risk for recurrence (assessed according to [46]) were seen. There was a weak correlation between ABL1 and KIT expression levels (r = 0.354). (m), metastatic; mult., multiple tumor nodules present; n/a, core not assessable.